Literature DB >> 17803957

CD4+ T cell acquisition of the bystander pMHC I colocalizing in the same immunological synapse comprising pMHC II and costimulatory CD40, CD54, CD80, OX40L, and 41BBL.

Tianpei He1, Sam Zong, Xiaochu Wu, Yangdou Wei, Jim Xiang.   

Abstract

We previously showed that CD4+ T cells acquired peptide/major histocompatibility complex (pMHC) I and costimulatory molecules by dendritic cell (DC) activation. However, the molecular mechanism for pMHC I acquisition is unclear. In this study, by using a panel of engineered DC2.4 cells or incubation of these cells with Con A-stimulated CD4+ T cells, we conducted capping and synapse formation assay and examined them by confocal fluorescence microscopy. We demonstrated that (i) CD54 and CD80 colocalized with pMHC I/II in the same lipid rafts, whereas CD40, OX40L, and 41BBL localized in the lipid rafts but separately from pMHC I/II, and (ii) MHC I/II colocalized with the costimulatory molecules in the same synapse formed between a DC and a CD4+ T cell, leading to expression of the acquired bystander pMHC I on CD4+ T cells via internalization/recycling pathway. These results provide some useful information in composition and dynamics of immunological synapses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17803957     DOI: 10.1016/j.bbrc.2007.08.072

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Tumor-derived HLA-G1 acquisition by monocytes through trogocytosis: possible functional consequences.

Authors:  Channakeshava Sokke Umeshappa; Jim Xiang
Journal:  Cell Mol Life Sci       Date:  2010-10-26       Impact factor: 9.261

2.  A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.

Authors:  Yufeng Xie; Lu Wang; Andrew Freywald; Mabood Qureshi; Yue Chen; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2012-10-08       Impact factor: 11.530

3.  CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.

Authors:  Haifeng Zhang; Yufeng Xie; Wei Li; Rajni Chibbar; Sidong Xiong; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2010-12-13       Impact factor: 11.530

4.  Colon cancer cells acquire immune regulatory molecules from tumor-infiltrating lymphocytes by trogocytosis.

Authors:  Jae Hun Shin; Jaekwang Jeong; Stephen E Maher; Heon-Woo Lee; Jaechul Lim; Alfred L M Bothwell
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-30       Impact factor: 12.779

Review 5.  Trogocytosis between Non-Immune Cells for Cell Clearance, and among Immune-Related Cells for Modulating Immune Responses and Autoimmunity.

Authors:  Ko-Jen Li; Cheng-Han Wu; Cheng-Hsun Lu; Chieh-Yu Shen; Yu-Min Kuo; Chang-Youh Tsai; Song-Chou Hsieh; Chia-Li Yu
Journal:  Int J Mol Sci       Date:  2021-02-24       Impact factor: 5.923

6.  Trogocytic intercellular membrane exchanges among hematological tumors.

Authors:  Joel LeMaoult; Julien Caumartin; Marina Daouya; Magdalena Switala; Vera Rebmann; Bertrand Arnulf; Edgardo D Carosella
Journal:  J Hematol Oncol       Date:  2015-03-14       Impact factor: 17.388

Review 7.  The Role of Trogocytosis in the Modulation of Immune Cell Functions.

Authors:  Kensuke Miyake; Hajime Karasuyama
Journal:  Cells       Date:  2021-05-19       Impact factor: 6.600

Review 8.  Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.

Authors:  Pablo A González; Leandro J Carreño; Pablo F Céspedes; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Clin Dev Immunol       Date:  2013-03-07

Review 9.  Mechanisms of cellular communication through intercellular protein transfer.

Authors:  Khawaja Ashfaque Ahmed; Jim Xiang
Journal:  J Cell Mol Med       Date:  2010-01-11       Impact factor: 5.310

Review 10.  The role of trogocytosis in immune surveillance of Hodgkin lymphoma.

Authors:  Qun Zeng; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2020-06-17       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.